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Abstract
AIM: To determine the tolerability and safety profile of a
low-dose maintenance therapy with 6-TG in azathioprine
(AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory
bowel disease (IBD) patients over a treatment period of
at least 1 year.
METHODS: Database analysis.
RESULTS: Twenty out of ninety-five (21%) patients
discontinued 6-TG (mean dose 24.6 mg; mean 6-TGN level
540 pmol/8×108 RBC) within 1 year. Reasons for
discontinuation were GI complaints (31%), malaise (15%)
and hepatotoxicity (15%). Hematological events occurred
in three patients, one discontinued treatment. In the
6-TG-tolerant group, 9% (7/75) could be classified as
hepatotoxicity. An abdominal ultrasound was performed
in 54% of patients, one patient had splenomegaly.
CONCLUSION: The majority of AZA or 6-MP-intolerant
IBD patients (79%) is able to tolerate maintenance
treatment with 6-TG (dosages between 0.3 and 0.4 mg/kg
per d). 6-TG may still be considered as an escape
maintenance immunosuppressant in this difficult to treat
group of patients, taking into account potential toxicity
and efficacy of other alternatives. The recently reported
hepatotoxicity is worrisome and 6-TG should therefore
be administered only in prospective trials.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Until now, no definite medical or surgical therapy is available
for the treatment of inflammatory bowel disease (IBD) as
the etiology remains essentially unknown. Therefore, the
aims of medical therapy in IBD are relief of symptoms
and to prevent long-term complications. Maintenance
therapy should preferably be efficient, safe, and cost-effective.
The immune modulating thiopurines 6-mercaptopurine
(6-MP) and its pro-drug azathioprine (AZA) have proven
efficacy in active IBD and in maintenance of an induced
clinical remission[1]. These thiopurines are prescribed on a
large scale in IBD and are considered as a mainstay
treatment option. However, issues concerning delayed onset
of activity, refractoriness, and toxicity have limited the
general use of AZA and 6-MP. In previous reports, up to
20% of patients discontinued AZA or 6-MP prematurely
due to adverse events[2]. The metabolism of thiopurines
has been partly elucidated in recent years (Figure 1). The
toxicity profile depends at least partly on the generated
metabolites of AZA and 6-MP[3]. At first, AZA is converted
to 6-MP by a non-enzymatic reaction, which is then
converted by a multi-step enzymatic pathway into a number
of active, inactive, or toxic metabolites. The efficacy of
AZA and 6-MP appears to be correlated with the formation
of the 6-thioguanine nucleotides (6-TGNs). During this
complex metabolization process, possible hepatotoxic
metabolites are generated under the influence of the enzyme
thiopurine methyltransferase (TPMT). The methylation
products of 6-MP, 6-methylmercaptopurine (6-MMP) and
their ribonucleotides, may be associated with hepatotoxicity[3].
Furthermore, flu-like symptoms, rashes, pancreatitis, and
neutropenia induced by AZA or 6-MP have recently been
related to mutations in the inosine triphosphate pyrophosphatase
(ITPase) gene leading to accumulation of the proposed
metabolite thio inosine triphosphate[4]. A possible strategy
to avoid AZA or 6-MP-induced toxicity is the administration
of a thiopurine, which is metabolically closer to the 6-TGNs.
The thiopurine 6-thioguanine (6-TG) is an attractive
candidate, which has the advantage of being directly
converted to 6-TGNs[5]. Therefore, treatment and safety
outcomes might be less sensitive for intra- and inter-individual
metabolic variations. Furthermore, due to the relative simple
metabolization, the number of possible toxic metabolites
is strongly reduced. Several open label studies in patients
with IBD have shown promising efficacy and acceptable
short-term toxicity of 6-TG[6,7]. More recently, the use of
6-TG has been associated with the induction of nodular
regenerative hyperplasia (NRH) of the liver. The aim of
the present study was to determine the tolerability and safety
profile of a low-dose maintenance therapy with 6-TG in
AZA or 6-MP intolerant IBD patients over a treatment
period of at least 1 year.
Figure 1  Metabolization process of thiopurines.
AZA is degraded to 6-MP and nitromethyl-imidazole,
via a non-enzymatic step. Three competing enzymes
metabolize 6-MP. Xanthine oxidase (XO) inactivates 6-MP
to 6-thiouric acid (6-TUA). TPMT methylates 6-MP, the
formed 6-MMP is associated with hepatotoxicity. By
hypoxanthine guanine phosphoribosyl transferase
(HPRT), 6-MP is catalyzed to 6-thioinosine monophosphate
(6-TIMP), then via inosine monophosphate dehydrogenase
to 6-thioxanthosine monophosphate, ultimately leading to
the pharmacologically active 6-TGN via the enzyme
guanosine monophosphate synthetase. 6-TIMP can also be
methylated to 6-methyl-TIMP. In a normal useless cycle,
6-TIMP is phosphorylated by monophosphate kinase to
6-thioinosine diphosphate, subsequently by diphosphate
kinase to 6-thioinosine triphosphate (6-TITP) and ultimately
back to 6-TIMP due to the ITPase. When ITPase activity
is impaired or lacking, 6-TITP accumulates. 6-TG is directly
converted by HPRT to 6-TGN. XO and TPMT metabolize
6-TG to 6-methyl-TG and 6-TUA, respectively. ITPase has
no known role in the metabolism of 6-TG.
MATERIALS AND METHODS
Patient selection
The study is a retrospective database analysis exploring
the tolerability and safety of 6-TG over at least a 1-year
treatment period in AZA or 6-MP-intolerant IBD patients,
treated in participating university and district hospitals in
the Netherlands. In each patient, the attending physician
judged the indication for administration of 6-TG. Some
patients have been described earlier in a short safety
assessment of 6-TG[6]. Patients were eligible for the study, if
they met the following in- and exclusion criteria. Inclusion criteria
were: age between 18 and 75 years, presence of confirmed
CD or UC with an indication for immunosuppressive
therapy, but in whom standard AZA or 6-MP therapy
failed, due to adverse events. Immunosuppression was
indicated in case of chronic active disease, corticosteroid
dependency or recurrent disease. Exclusion criteria were
pregnancy, lactation, presence of active infection, history
of tuberculosis, HIV, hepatitis B or C, history of severe
pancreatitis (necrotizing pancreatitis or pancreatitis leading
to multi-organ-failure), ongoing treatment with concomitant
immunosuppressive drugs (e.g., cyclosporine, methotrexate
(MTX), thalidomide or infliximab), impaired renal function
(serum creatinine >2 times normal upper limit), impaired
hepatic function (>2 times normal upper limit) and persistent
bone marrow suppression.
Study design
In all patients, 6-TG (Lanvis®, tablet 40 mg, Glaxo Wellcome)
was administered orally in a dose of 20-40 mg once daily
based on the decision of the attending physician. The
following data were collected: patient demographics, history
of thiopurine exposure, type of thiopurine intolerance, the
use of concomitant medication, blood cell counts, and
liver enzymes were recorded. Dose of 6-TG, duration of
6-TG, occurrence of adverse events, blood cell counts, and
liver enzymes were reviewed after a minimum of 12 mo
after initiation of 6-TG treatment. During the described
period, the genotyping of TPMT became available and in a
subgroup of patients the TPMT status was determined.
RBC 6-TGN levels were determined at least 4 wk after
giving a stable dose in order to obtain steady-state levels of
6-TGN. Dose adjustments were left to the discretion of
the attending physician, but when 6-TGN levels were above
1 000-1 500 pmol/8×108 RBC, dose reduction was
contemplated. In case of a leukocyte count below 3.5×109/L,
dose reduction was advocated and in case of severe
leukopenia (below 1.0×109/L) 6-TG had to be discontinued.
Additionally, in order to explore signs of hepatotoxicity, an
abdominal ultrasonography was advised after at least 1-year
6-TG administration. Special attention was paid to
splenomegaly, signs of portal hypertension, and hepatic
changes.
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Outcome measurements
Primary outcome measures were the ability to tolerate
6-TG and the occurrence of adverse events leading to
discontinuation of 6-TG over the 1-year period. The
relationship of any adverse event with the use of 6-TG
was established by the following method: unrelated, no
temporal relation and other etiology likely; possibly related,
potential temporal relation and other etiologies possible;
probably related, potential temporal relation and other
etiologies unlikely; related, clear temporal relation not
otherwise explained. Secondary outcome measures were the
occurrence of hematological events (defined as leukocyte
count <4.0×109/L or platelet count <100×109/L), the
occurrence of hepatotoxicity (defined as a rise of at least
two times the upper normal limit of a single liver enzyme
level), pancreaticotoxicity (serum amylase >220 U/L) and
signs of liver-related abnormalities on the abdominal
ultrasound. The following data concerning disease activity
were analyzed as well: ESR, C-reactive protein (CRP), serum
albumin and a global physician assessment score (features
were same, better or worse).
6-TG metabolite monitoring and genotyping of TPMT
Blood samples for 6-TGN measurements were obtained at
least 4 wk after the onset of a stable 6-TG dose. The samples
were centrifuged to isolate erythrocytes and after washing
with PBS, erythrocyte counts were done. Samples were
stored at -20 ¡æ until required. RBC 6-TGN levels were
measured in the laboratory of the Department of Clinical
Pharmacy, Maasland Hospital Sittard, using a proprietary
modified previously published assay[8]. The lower limit of
quantification of the assay was 30 pmol/8×108 RBC for
6-TGN levels with a run-to-run coefficient of variation of
6.6%. Extra blood samples were drawn once during the
1-year period to assess TPMT (G238C, G460A and A719G,
i.e., TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C)
genotypes in a sub-group of patients, independent of the
biochemical or clinical status. The genotyping was performed
at the Department of Gastroenterology and Hepatology at
the Academic Medical Centre in Amsterdam.
Statistical analysis
Data are expressed as mean±SD. Significance was evaluated
by a t test for paired or independent data; P values of less
than 0.05 were considered significant. Pearson’s correlation
was used to determine relationships between parameters. A
χ2 test was used to determine the significance between the
TPMT genotype and 6-TG intolerance. SPSS for Windows
version 11.0 was used for statistical analysis.
RESULTS
Patients
In 95 patients, treatment with 6-TG was initiated in the period
from June 2001 to July 2003. Fifty-eight patients (61%)
were female (mean age: 40 years, range: 20-74 years) and
37 (39%) were male (mean age: 47 years, range: 20-71 years).
Forty-two (44%) patients were diagnosed with UC compared
to 53 (56%) patients with CD. All patients were intolerant
to AZA, 6-MP or both. The adverse events leading to
discontinuation of AZA or 6-MP use were gastrointestinal
complaints, general malaise, allergic reactions, hepatotoxicity
or myelotoxicity. The patient’s characteristics are given in
detail in Table 1. The mean initial 6-TG dose was 24.6 mg
(range 20-40 mg). The mean initial 6-TG dose adjusted to
bodyweight was 0.37 mg/kg (SD 0.16 mg/kg).
Table 1  Patients’ characteristics
              n = 95 patients
Female:male               58:37 patients
Age (yr)               43 years (range 20–74 yr)
UC:CD               42:53 patients
Duration of IBD at start 6-TG               10.4 yr (SD 9.4 yr)
AZA intolerance               78 patients (82%)
6-MP intolerance               4 patients (4%)
AZA and 6-MP intolerance               13 patients (14%)
AZA or 6-MP rechallenge               36 patients (38%)
Adverse events on AZA or 6MP:               30% gastrointestinal complaints
              20% general malaise
              14% allergic reactions
              10% pancreaticotoxicity
              6% hepatotoxicity
              5% myelotoxicity
              14% rest (e.g., myalgia or alopecia)
6-TG dosage at the start               24.6 mg (range 20-40 mg)
Primary outcome
Seventy-five (79%) of the ninety-five patients were able to
tolerate 6-TG during 1-year use. In 20 (21%) patients, the
administration was discontinued due to side effects. The 20
intolerant patients (9 females and 11 males) encountered
26 side effects. The data concerning the adverse events
leading to withdrawal and the relationship with 6-TG use
are summarized in Table 2. No mortality was reported. The
mean 6-TG dosage was 0.30 mg/kg in the tolerant group
compared to 0.34 mg/kg in the intolerant group (NS).
Table 2  Adverse events (n  = 26) leading to discontinuation of 6-TG
use in 20 patients (AE, adverse event; 6-TG, 6-thioguanine; GI
complaints, gastrointestinal complaints)
AE on 6-TG       Frequency Mean time         Relationship
             (%)   to AE (d)          with 6-TG
GI complaints        8/26 (31)         43             Probably 6/8 possibly 2/8
Hepatotoxicity        4/26 (15)      182             Probably 2/4 possibly ¼
            unrelated 1/4
Myelodepression        1/26 (4)         50             Related
Pancreaticotoxicity      1/26 (4)      103             Possibly
General malaise        4/26 (15)         51             Probably 3/4 possibly ¼
Allergic reaction        1/26 (4)         1             Related
Other AE        7/26 (27)         39             Related 1/7 probably
            2/7 possibly 4/7
Secondary outcomes
Hematological events  Three patients had signs of
myelosuppression. One patient had a leukocyte count of
3.2×109/L and a platelet count of 70×109/L after 50 d of
6-TG use (20 mg). Subsequently, 6-TG was discontinued.
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The second patient had a leukopenia (leukocytes 3.5×109/L)
and a third patient had a thrombocytopenia (platelets
87×109/L) at 1-year measurements, both did not discontinue
6-TG. All other patients, both tolerant and intolerant to 6-TG,
had platelet and leukocyte counts above the set lower limits.
However, the mean platelet count decreased significantly
from baseline (309×109/L) to 1 year of 6-TG treatment
(290×109/L, P = 0.033). The mean leukocyte count
decreased as well (from 11.9 to 7.8×109/L) though not
significantly. The 6-TGN level did not correlate with the
decrease in both leukocytes or platelets counts. Hemoglobin
levels remained unchanged in both patient groups.
Hepatotoxicity and pancreaticotoxicity  In the 6-TG
tolerant group the ASAT, ALAT, GGT, and AP levels
were determined in 65%, 71%, 60%, and 68% of patients
at 1-year 6-TG use, respectively. The mean levels of ASAT,
ALAT, GGT, and AF were 24.7 U/L (range 6-118 U/L),
24.5 U/L (range 5-206 U/L), 48 U/L (range 6-535 U/L),
and 84 U/L (range 42-322 U/L), respectively. A significant
increase in liver enzymes during treatment in the tolerant
group was not established. At 1-year use, in 9% of patients
(7/75) hepatotoxicity occurrence on 6-TG treatment could
be classified. Four patients (4/20) of the intolerant group
discontinued 6-TG use due to hepatotoxicity. All had normal
liver tests at entry and three of these patients encountered
allergic reactions but no hepatotoxicity on the prior AZA
therapy. Three patients had a serum amylase level above
220 U/L before the start of 6-TG that all became normal
during treatment. One patient developed a transitory
symptomatic pancreatitis with a serum amylase level of
430 U/L during 6-TG treatment and discontinued treatment.
Abdominal ultrasonography  In 51 patients (54%), an
abdominal ultrasonography was performed after at least
1 year 6-TG use. Five ultrasounds (10%) were considered
as abnormal; three patients with steatosis, one patient had a
choledocholithiasis and the last patient had a hydrops of
the gallbladder and a splenomegaly (spleen size 13 cm). The
latter two patients were classified as hepatotoxicity on 6-TG
treatment.
Disease activity parameters  No significant decrease in
CRP (15-11 mg/L) or ESR level (15-14 mm) was established
in the 6-TG tolerant group. The albumin level increased
(37.6-40.1 g/L) significantly in the tolerant group (P = 0.002).
A significant decrease of albumin level (38.5-36.6 g/L) was
established in the intolerant group (P = 0.03). The global
physician score was determined at 1-year 6-TG use in 85%
(64/75) of the tolerant patients. Forty-seven patients (73%)
were classified as better, 15 patients (23%) as the same and
4 patients (6%) as worse during 6-TG treatment.
6-TG metabolite monitoring and genotyping of TPMT
The mean steady state 6-TGN level, determined in 63%
(47/75) of the tolerant patients, was 540 pmol/8×108 RBC
(SD 245, range 0-1 404). In the eight intolerant patients in
whom metabolite levels were measured (40%), the 6-TGN
level was 725 pmol/8×108 RBC (SD 422, range 229-1 563).
The difference in 6-TGN levels between tolerant and
intolerant patients was not significant. No statistical significant
correlations were established between laboratory parameters
(leukocytes, platelets, hemoglobin, AF, GGT, ASAT, and
ALAT) and 6-TGN level. The TPMT genotyping was
performed in 51 patients (54%). Two patients (3.9%) had
one mutant non-functional allele (TPMT*3A and
TPMT*3C) and both patients were intolerant for 6-TG
(myelodepression and hepatotoxicity) (significant, P = 0.003).
The 6-TGN level was not determined in both patients.
Patients with two mutant non-functional alleles of TPMT
(homozygous mutants) were not found in our population.
DISCUSSION
In this group of AZA or 6-MP-intolerant IBD patients, we
demonstrated that 6-TG in dosages of 0.3-0.4 mg/kg daily
was well tolerated over a period of 1 year as a maintenance
immunosuppressant in 79% of the patients. This result
suggests that during the metabolization process of AZA or
6-MP metabolites are generated that induce side effects,
which at least in part are not generated during the 6-TG
metabolism. No mortality was reported due to 6-TG use.
When 6-TG was discontinued, the side effects leading to
withdrawal resolved spontaneously. One patient developed
a myelodepression that may be explained by the impaired
TPMT activity, probably shunting 6-TG away from
methylation by TPMT toward the formation of 6-TGNs,
which have been associated with myelotoxicity. Unfortunately,
no 6-TGN level was determined in this patient. The real
incidence of 6-TG-related histological liver abnormalities
like NRH or veno-occlusive disease (VOD) in the present
study remains unknown, as liver biopsies were not performed.
The incidence of 6-TG related increase in liver enzymes
probably will be lower than 7 out of 75 patients, as 2 patients
already had abnormal liver tests before the start of 6-TG
and 1 patient had symptomatic choledocholithiasis.
In the present study, we found a mean 6-TGN level of
540 pmol/8×108 RBC in the tolerant group, which is above
the proposed therapeutic threshold of 250 pmol/8×108
RBC and even higher than the proposed upper limit of
efficacy (450 pmol/8×108 RBC) under AZA or 6-MP
therapy[3,9]. This is consistent with previous observations[6,7].
It remains to be elucidated whether the same 6-TGN limits
should be used when 6-TG is administered. In our study,
73% clinically benefited from 6-TG by using the global
physician score and the mean albumin level increased
significantly. However, due to the retrospective nature of
the study, we must be reserved in drawing firm conclusions
as no standard efficacy parameters as the Crohn’s disease
activity index or Truelove-Witts index were used. Despite
the fact that we have not demonstrated a significant
relationship between 6-TGN levels, laboratory results and
adverse events, we believe that therapeutic drug monitoring
may be a helpful tool in dosing 6-TG. Extremely high 6-TGN
levels, which have been associated with an increased risk
of developing myelotoxicity, can be prevented and
compliance can be monitored.
The TPMT status has been associated with the ability
to tolerate AZA or 6-MP. Patients with impaired TPMT
activity are more prone to develop a myelodepression[10].
However, our study demonstrates that in AZA or 6-MP-
intolerant patients only two patients (3.9%) had one mutant
TPMT allele, which is even lower than the incidence in the
normal Caucasian population[11]. Interestingly, both patients
did not develop a myelodepression on AZA therapy. This
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indicates that other metabolic pathways may lead to toxicity
of AZA or 6-MP as was recently demonstrated for the
ITPase routing (Zelinkova et al., submitted for publication).
However, both patients with one mutant TPMT allele
discontinued the use of 6-TG. Unfortunately, in these
patients no 6-TGN concentrations were measured before
discontinuation of 6-TG. Possibly, an impaired TPMT
activity leads to more 6-TG being metabolized by the
enzymes HGPRT or XO leading to higher 6-TGN and
6-TUA levels, respectively (Figure 1). The accumulation of
these metabolites may lead to intolerance of 6-TG.
Recently, the use of 6-TG in IBD patients has been
associated with the induction of NRH and VOD[12]. In the
present study, we performed an abdominal ultrasonography
after at least 1-year 6-TG use to screen for possible
hepatotoxicity in 51 patients. Only one patient showed signs
of portal hypertension indicated by an enlarged spleen.
NRH has been associated with thrombocytopenia[16] and
in our evaluation only two patients had platelets counts
below 100 U/L. We are well aware of the fact that by using
biochemistry and ultrasound outcomes, we probably
underestimate the real incidence of 6-TG-induced NRH,
as the golden standard is based on histology. Additionally,
liver tests abnormalities were shown not to be indicative
for NRH. Conversely, it should be taken into account
that AZA and 6-MP can induce NRH or VOD as well, but
performing liver biopsies during treatment with these
compounds is not recommended in clinical practice.
Currently, the use of 6-TG in IBD patients is abandoned
due to potential hepatotoxicity[12]. However, low-dose 6-TG
may still be considered as an escape maintenance strategy
in AZA- or 6-MP-intolerant IBD patients whom are
refractory for alternative therapies. The number of proven
effective medical maintenance options is scarce for these
patients. MTX has a reasonable toxicity profile and seems
effective in CD, comparable with AZA or 6-MP[13] but the
potential use of MTX in UC patients has yet to be proven.
In addition, long-term use of MTX may be limited[14].
Cyclosporine seems to have no role as a maintenance
immunosuppressive alternative in IBD[15]. Infliximab can
be administered as a maintenance option in CD with
acceptable toxicity and may be effective in treating UC.
However, concomitant immunosuppressive therapy with
thiopurines or MTX next to infliximab therapy seems
mandatory to reduce the immunogenic response[16].
Treatment with 6-TG is well tolerated in AZA and 6-
MP-intolerant IBD patients and seems to be effective.
We believe that low-dosed 6-TG (0.3-0.4 mg/kg per d)
maintenance therapy may still be an escape option for this
difficult to treat group of patients. The benefit of 6-TG
use in this sub-group may balance its toxicity profile,
especially taking into account the toxicity and efficacy
of other therapeutic alternatives. Still, the reported
hepatotoxicity is worrisome and 6-TG should therefore be
administered only in prospective clinical trials.
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